WBC
GSK icon

West Branch Capital’s GSK GSK Stock Holding History

West Branch Capital’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-7
Closed -$307 – 579
2024
Q3 		$307 Buy
+7
New +$286 ﹤0.01% 439
2023
Q4 		– Sell
-1,320
Closed -$47.9K – 450
2023
Q3 		$47.9K Hold
1,320
– – 0.03% 165
2023
Q2 		$47K Hold
1,320
– – 0.02% 168
2023
Q1 		$47K Sell
1,320
-80
-6% -$2.8K 0.03% 172
2022
Q4 		$49.2K Hold
1,400
– – 0.03% 169
2022
Q3 		$41K Sell
1,400
-36
-3% -$1.36K 0.03% 181
2022
Q2 		$78K Buy
1,436
+36
+3% +$1.99K 0.05% 138
2022
Q1 		$76K Sell
1,400
-505
-27% -$27.4K 0.04% 154
2021
Q4 		$95K Buy
1,905
+505
+36% +$26.3K 0.04% 149
2021
Q3 		$67K Hold
1,400
– – 0.03% 166
2021
Q2 		$70K Buy
+1,400
New +$67.3K 0.03% 171

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

West Branch Capital's GSK Position: Q4 2024 in Review

West Branch Capital sold out of GSK (GSK) in Q4 2024, closing a stake of 7 shares — an estimated $307 sold.

West Branch Capital first reported a position in GSK in Q2 2021 and held it in 11 quarters. The position peaked at $95K in Q4 2021. 848 funds tracked by Wall St. Rank hold GSK as of Q4 2024.

  • West Branch Capital reported no remaining GSK position as of Q4 2024 after selling out during the quarter.
  • West Branch Capital sold 7 GSK shares in Q4 2024, an estimated $307.
  • West Branch Capital first reported a position in GSK in Q2 2021 and held it in 11 quarters.
  • West Branch Capital's GSK position peaked at $95K in Q4 2021.
  • 848 funds tracked by Wall St. Rank held GSK as of Q4 2024.

Based on West Branch Capital's 13F filing for Q4 2024, filed 17 Jan 2025.